- Home
- TKLF vs IBIO Comparison
TKLF vs IBIO Comparison
Compare TKLF & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- IBIO
- Stock Information
- Founded
- TKLF 2006
- IBIO 2008
- Country
- TKLF Japan
- IBIO United States
- Employees
- TKLF N/A
- IBIO N/A
- Industry
- TKLF Other Specialty Stores
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- IBIO Health Care
- Exchange
- TKLF Nasdaq
- IBIO Nasdaq
- Market Cap
- TKLF 16.0M
- IBIO 15.9M
- IPO Year
- TKLF 2022
- IBIO N/A
- Fundamental
- Price
- TKLF $3.56
- IBIO $0.71
- Analyst Decision
- TKLF
- IBIO Strong Buy
- Analyst Count
- TKLF 0
- IBIO 3
- Target Price
- TKLF N/A
- IBIO $4.87
- AVG Volume (30 Days)
- TKLF 10.6K
- IBIO 5.3M
- Earning Date
- TKLF 07-15-2025
- IBIO 05-02-2025
- Dividend Yield
- TKLF N/A
- IBIO N/A
- EPS Growth
- TKLF N/A
- IBIO N/A
- EPS
- TKLF 1.70
- IBIO N/A
- Revenue
- TKLF $219,520,631.00
- IBIO $375,000.00
- Revenue This Year
- TKLF N/A
- IBIO $36.00
- Revenue Next Year
- TKLF N/A
- IBIO N/A
- P/E Ratio
- TKLF $2.18
- IBIO N/A
- Revenue Growth
- TKLF 32.02
- IBIO 650.00
- 52 Week Low
- TKLF $2.20
- IBIO $0.64
- 52 Week High
- TKLF $8.53
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- TKLF 51.46
- IBIO 37.70
- Support Level
- TKLF $3.20
- IBIO $0.68
- Resistance Level
- TKLF $3.85
- IBIO $1.04
- Average True Range (ATR)
- TKLF 0.20
- IBIO 0.12
- MACD
- TKLF -0.02
- IBIO -0.00
- Stochastic Oscillator
- TKLF 60.93
- IBIO 7.89
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.